HEMODYNAMICALLY SIGNIFICANT PATENT DUCT ARTERIUS IN PREMATURE NEWBORN CHILDREN. LITERATURE REVIEW

Author(s): Omargazina B.S, Chuvakova T.K, Karin B.T, Dzhaksalykova K.K. , Khamidullina Z.G

DOI: 10.34689/SH.2024.26.2.020

Introduction. Hemodynamically significant patent ductus arteriosus (PDA) is the most common cardiovascular disease in premature newborns, and remains a frequently discussed issue in neonatology. To this day, there is no clarity in determining the hemodynamic significance of the patent ductus arteriosus, and to this day there is no consensus on this matter. This explains the lack of clear algorithms and certainty in the management of PDA in premature newborns around the world. There are also no clear algorithms regarding treatment, selection of drugs, doses, routes and frequency of drug administration. This often leads to subjectivity in therapy, delays in the start of treatment, and unsuccessful attempts at treatment to close the duct. Purpose of the study. To review current and relevant research on the management and treatment of patent ductus arteriosus in preterm infants through a literature review. Search strategy. A search for open access publications was conducted using databases of scientific publications and specialized search engines: PubMed, Google Scholar, Cochrane Library, Scopus, Web of Science. A number of original articles and reviews on the research topic over the past 5 years were analyzed, this is the period 2018-2023, but works published earlier than 2018 were also included, since they have information on the topic under study and the basics of the pathogenesis and pathophysiology of the nasology under study, classical routine approaches to treatment and diagnosis in premature newborns. Key words used: hemodynamically significant patent ductus arteriosus, echocardiography, preterm neonates.As a result of the search, we examined 116 publications, and this review included 82 publications. Results. In the world on its definition of PDA and management tactics. On the one hand, the qualitative and quantitative determination of the hemodynamic significance of a PDA based on clinical signs, echocardiographic parameters, on the other hand, the determination of clear indications for starting treatment based on the variable parameters for determining the PDA, on the third hand, the determination of the prognosis when a PDA is most likely to have an adverse hemodynamic effect, with the purpose of identifying the category of patients at high risk of serious complications. Echocardiography (EchoCG) is the “gold standard” in determining the presence of a PDA and its hemodynamic significance. There are echocardiographic indicators that allow one to determine the hemodynamic significance of a patent ductus arteriosus. Various scoring systems have been developed that integrate risk factors, clinical data, and echocardiographic measurements and have been developed to help the clinician identify PDA and predict outcomes. Although echocardiographic and clinical parameters have been extensively studied, the relationship of PDA with various complications and outcomes requires further research. Conclusions. Further research is needed to help determine the best clinical strategy to treat hemodynamically significant ductus with maximum safety and effectiveness in neonatal patients. Research is still ongoing to determine the criteria for the hemodynamic significance of patent ductus arteriosus, and treatment issues are also being actively studied. In addition to clinical assessment, a competent echocardiographic examination of the heart is important for the correct diagnosis of PDA and determination of its hemodynamic significance; Doppler assessment of organ blood flow parameters is especially important for assessing perfusion disorders. Any type of treatment, both drug therapy and surgical intervention, is imperfect and has its own disadvantages and risks, which are important to remember and make informed decisions when choosing clinical tactics for a newborn patient.

Botagoz S. Omargazina1, https://orchid.org/0000-0001-7157-5782 Tamara K. Chuvakova1, https://orcid.org/0000-0001-5411-8061 Bekturgan T. Karin1, https://orcid.org/0000-0002-8080-787X Kulyash K. Jaxalykova1, https://orcid.org/0000-0001-5540-3331 Zaituna G. Khamidullina1, https://orcid.org/0000-0002-5324-8486 1 NJSC " Astana Medical University", Astana, the Republic of Kazakhstan.

1. Иштван Сери, Чарльз Клайман Гемодинамика и кардиология. Проблемы и противоречия в неонатологии. Москва. Логосфера. 2015. С. 119-120. 2. Aikio O., Härmä A., Härkin P., Leskinen M., Valkama M., Saarela T., Salminen A., Hallman M. Inflammatory biomarkers in very preterm infants during early intravenous paracetamol administration // Early Hum Dev. 2021. 161:105464. 3. Al-Matary A., Abu Shaheen A., Abozaid S. Use of Prophylactic Indomethacin in Preterm Infants: A Systematic Review and Meta-Analysis // Front Pediatr. 2022.10:760029. 4. Al-Shaibi S., Abushanab D., Alhersh E., Kaddoura R., Pallivalappila A.R., Al-Badriyeh D. Use of ibuprofen for the closure of patent ductus arteriosus in preterm infants: a systematic review of meta-analyses // J Comp Eff Res. 2021. 10(7):549-568. 5. Apalodimas L., Waller B.R., Philip R., Crawford J., Cunningham J., Sathanandam S. A comprehensive program for preterm infants with patent ductus arteriosus // Congenit Heart Dis. 2019. 14(1):90-94. 6. Asbury M.R., Unger S., Kiss A., Ng D.V., Luk Y., Bando N., Bishara R., Tomlinson C., O'Connor D.L. Optimizing the growth of very-low-birth-weight infants requires targeting both nutritional and nonnutritional modifiable factors specific to stage of hospitalization // Am J Clin Nutr. 2019.110(6):1384-1394. 7. Aw T.C., Chan B., Singh Y. Transport and Anaesthesia Consideration for Transcatheter Patent Ductus Arteriosus Closure in Premature Infants // J Cardiovasc Dev Dis. 2023. 10(9):377. 8. Backes C.H., Hill K.D., Shelton E.L., Slaughter J.L., Lewis T.R., Weisz D.E., Mah M.L., Bhombal S., et al. Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider // J Am Heart Assoc. 2022. 11(17):e025784. 9. Balachander B., Mondal N., Bhat V., Adhisivam B., Kumar M., Satheesh S., Thulasingam M. Comparison of efficacy of oral paracetamol versus ibuprofen for PDA closure in preterms - a prospective randomized clinical trial // J Matern Fetal Neonatal Med. 2020. 33(9):1587-1592. 10. Balasubramanian H., Jain V., Bhalgat P., Parikh S., Kabra N., Mohan D., Sheth K. Low dose paracetamol for management of patent ductus arteriosus in very preterm infants: a randomised non-inferiority trial // Arch Dis Child Fetal Neonatal Ed. 2023. 108(2):130-135. 11. Bell J.L, Gupta S., Juszczak E., Hardy P., Linsell L. Baby-OSCAR: Outcome after Selective early treatment for Closure of patent ductus Arteriosus in preterm babies-a statistical analysis plan for short-term outcomes // Trials. 2021. 22(1):368. 12. Bitar E., Hyderi A., Campbell S.M., Kumar M. Acetaminophen versus indomethacin for patent ductus arteriosus management in premature infants: systematic review and meta-analysis of randomized controlled trials // Paediatr Child Health. 2023. 28(5):291-298. 13. Borges-Lujan M., Gonzalez-Luis G.E., Roosen T., Huizing M.J., Villamor E. Sex Differences in Patent Ductus Arteriosus Incidence and Response to Pharmacological Treatment in Preterm Infants: A Systematic Review, Meta-Analysis and Meta-Regression // J Pers Med. 2022. 12(7):1143. 14. Bussmann N., Smith A., Breatnach C.R., McCallion N., Cleary B., Franklin O., McNamara P.J., El-Khuffash A. Patent ductus arteriosus shunt elimination results in a reduction in adverse outcomes: a post hoc analysis of the PDA RCT cohort // J Perinatol. 2021.41(5):1134-1141. 15. Chan B., Singh Y. Personalized Evidence-Based Management of Patent Ductus Arteriosus in Preterm Infants // J Cardiovasc Dev Dis. 2023. 11(1):7. 16. Chock V.Y., Bhombal S., Variane G.F., Van Meurs K.P., Benitz W.E. Ductus arteriosus and the preterm brain // Arch Dis Child Fetal Neonatal Ed. 2023. 108(2):96-101. 17. Cheema H.A., Majeed Z., Hayat T., Ahmed A., Tariq M.H., Shahid A., Titus A., Minhas A.M., et al. Expectant management of patent ductus arteriosus for preterm infants: A meta-analysis of randomized controlled trials // Am Heart J. 2023. 266:179-183. 18. Dani C., Pratesi S. Patent ductus arteriosus and oxidative stress in preterm infants: a narrative review // Transl Pediatr. 2020. 9(6):835-839. 19. Delara M., Chauhan B.F., Le M.L., Abou-Setta A.M., Zarychanski R., 'tJong G.W. Efficacy and safety of pulmonary application of corticosteroids in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis // Arch Dis Child Fetal Neonatal Ed. 2019.104(2):F137-F144. 20. de Klerk C.A., Engbers A.G., van Beek F., Flint R.B., Reiss I.K., Völler S., Simons S.H. Spontaneous Closure of the Ductus Arteriosus in Preterm Infants: A Systematic Review // Front Pediatr. 2020. 8:541. 21. de Waal K., Phad N., Stubbs M., Chen Y., Kluckow M. A Randomized Placebo-Controlled Pilot Trial of Early Targeted Nonsteroidal Anti-Inflammatory Drugs in Preterm Infants with a Patent Ductus Arteriosus // J Pediatr. 2021. 228:82-86.e2. 22. Ding R., Zhang Q., Duan Y., Wang D., Sun Q., Shan R. The relationship between platelet indices and patent ductus arteriosus in preterm infants: a systematic review and meta-analysis // Eur J Pediatr. 2021. 180(3):699-708. 23. Edison P.E., Chen S., Yeo C.L., Allen J.C. Jr, Poon W.B., Baral V.R., Chowbay B. Pharmacokinetics of oral versus intravenous ibuprofen for closure of patent ductus arteriosus: A pilot randomised controlled study // J Paediatr Child Health. 2022. 58(3):397-403. 24. El-Khuffash A., Bussmann N., Breatnach C.R., Smith A., Tully E., Griffin J., McCallion N., Corcoran J.D., Fernandez E., Looi C., Cleary B., Franklin O., McNamara P.J. A Pilot Randomized Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score (The PDA RCT) // J Pediatr. 2021.229:127-133. 25. Eursiriwan S., Okascharoen C., Vallibhakara S.A., Pattanaprateep O., Numthavaj P., Attia J., Thakkinstian A. Comparison of Various Pharmacologic Agents in the Management of Hemodynamically Significant Patent Ductus Arteriosus in Preterm: A Network Meta-Analysis and Risk-Benefit Analysis // Biomed Hub. 2022. 7(3):125-145. 26. Evans P., O'Reilly D., Flyer J.N., Soll R., Mitra S. Indomethacin for symptomatic patent ductus arteriosus in preterm infants // Cochrane Database Syst Rev. 2021. 1(1):CD013133. 27. Fraisse A., Bautista-Rodriguez C., Burmester M., Lane M., Singh Y. Transcatheter Closure of Patent Ductus Arteriosus in Infants With Weight Under 1,500 Grams // Front Pediatr. 2020. 8:558256. 28. Francescato G., Doni D., Annoni G., Capolupo I., Ciarmoli E., Corsini I., Gatelli I.F., Salvadori S., Testa A., Butera G. Transcatheter closure in preterm infants with patent ductus arteriosus: feasibility, results, hemodynamic monitoring and future prospectives // Ital J Pediatr. 2023.49(1):147. 29. Ghouse F., Idrobo Zapata C., Kasam Shiva P.K., Aguilar A., Siripragada R., Nair N., Vera E., Suresh A. Closing the Gap: Investigation of Various Approaches in the Management of Patent Ductus Arteriosus // Cureus. 2023. 15(9):e45009. 30. Gonzalez-Luis G.E., Borges-Lujan M., Villamor E. Association between endotypes of prematurity and pharmacological closure of patent ductus arteriosus: A systematic review and meta-analysis // Front Pediatr. 2023. 11:1078506. 31. González-Luis G., Ghiradello S., Bas-Suárez P., Cavallaro G., Mosca F., Clyman R.I., Villamor E. Platelet Counts and Patent Ductus Arteriosus in Preterm Infants: An Updated Systematic Review and Meta-Analysis // Front Pediatr. 2021. 8:613766. 32. Hamrick S., Sallmon H., Rose AT., Porras D., Shelton E.L., Reese J., Hansmann G. Patent Ductus Arteriosus of the Preterm Infant // Pediatrics. 2020. 146(5):2020-1209. 33. Hundscheid T., Donders R., Onland W., Kooi E.M., Vijlbrief D.C., de Vries WB., Nuytemans D.H., van Overmeire B., Mulder A.L., de Boode W.P. BeNeDuctus trial study group. Multi-centre, randomised non-inferiority trial of early treatment versus expectant management of patent ductus arteriosus in preterm infants (the BeNeDuctus trial): statistical analysis plan // Trials. 2021.22(1):627. 34. Hundscheid T., Jansen E.J., Onland W., Kooi E.M., Andriessen P., de Boode W.P. Conservative Management of Patent Ductus Arteriosus in Preterm Infants-A Systematic Review and Meta-Analyses Assessing Differences in Outcome Measures Between Randomized Controlled Trials and Cohort Studies // Front Pediatr. 2021. 9:626261. 35. Hundscheid T., Onland W., Kooi E.M., Vijlbrief D.C., de Vries W.B., Dijkman K.P., van Kaam A.H., Villamor E., et al. Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus // N Engl J Med. 2023. 388(11):980-990. 36. Hundscheid T., van den Broek M., van der Lee R., de Boode W.P. Understanding the pathobiology in patent ductus arteriosus in prematurity-beyond prostaglandins and oxygen // Pediatr Res. 2019. 86(1):28-38. 37. Jansen E.J., Hundscheid T., Onland W., Kooi E.M., Andriessen P., de Boode W.P. Factors Associated With Benefit of Treatment of Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-Analysis // Front Pediatr. 2021. 9:626262. 38. Jasani B., Mitra S., Shah P.S. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants // Cochrane Database Syst Rev. 2022. 12:CD010061. 39. Jasani B., Weisz D.E., Reese J., Jain A. Combination pharmacotherapy for patent ductus arteriosus: Rationale and evidence // Semin Perinatol. 2023. 47(2):151720. 40. Kaur S., Manerkar S., Mondkar J., Kalamdani P., Patra S., Kalathingal T. The dilemma of feeding during the treatment of patent ductus arteriosus with oral ibuprofen in preterm infants ≤30 weeks of gestation-a randomized controlled trial // J Perinatol. 2023. 43(2):203-208. 41. Khowaja W., Akhtar S., Jiwani U., Mohsin M., Shaheen F., Ariff S. Outcomes of preterm neonates with patent ductus arteriosus: A retrospective review from a tertiary care hospital // J Pak Med Assoc. 2022. 72(10):2065-2068. 42. Kumar J., Dutta S., Sundaram V., Saini S.S., Sharma R.R., Varma N. Platelet Transfusion for PDA Closure in Preterm Infants: A Randomized Controlled Trial // Pediatrics. 2019. 143(5):e20182565. 43. Lalitha R., Surak A., Bitar E., Hyderi A., Kumaran K. Fluid and electrolyte management in preterm infants with patent ductus arteriosus // J Neonatal Perinatal Med. 2022.15(4):689-697. 44. Lavie-Nevo K., Dinur G., Almagor Y., Barzilay B., Rotschild A., Gover A. Functional ECHO in preterm infant – past, present, future // Harefuah. 2020.159(10):759-763. 45. Lembo C., El-Khuffash A., Fusch C., Iacobelli S., Lapillonne A. ESPR Nutrition council members. Nutrition of the preterm infant with persistent ductus arteriosus: existing evidence and practical implications // Pediatr Res. 2023. Epub ahead of print. 46. Marconi E., Bettiol A., Ambrosio G., Perduca V., Vannacci A., Troiani S., Dani C., Mugelli A., Lucenteforte E. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: A systematic review and network meta-analysis of clinical trials and observational studies // Pharmacol Res. 2019. 148:104418. 47. Martini S., Aceti A., Galletti S., Beghetti I., Faldella G., Corvaglia L. To Feed or Not to Feed: A Critical Overview of Enteral Feeding Management and Gastrointestinal Complications in Preterm Neonates with a Patent Ductus Arteriosus // Nutrients. 2019. 12(1):83. 48. Mitra S., de Boode W.P., Weisz D.E., Shah P.S. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews // Cochrane Database Syst. Rev. 2023.4(4):CD013588. 49. Mitra S., Weisz D., Jain A., Jong G'. Management of the patent ductus arteriosus in preterm infants // Paediatr Child Health. 2022.27(1):63-64. 50. Mitra S., McNamara P.J. Patent Ductus Arteriosus-Time for a Definitive Trial // Clin Perinatol. 2020.47(3):617-639. 51. Olowoyeye A., Nnamdi-Nwosu O., Manalastas M., Okwundu C. A Network Meta-Analysis of Intravenous Versus Oral Acetaminophen for Patent Ductus Arteriosus // Pediatr Cardiol. 2023. 44(4):748-756. 52. Ohlsson A., Shah S.S. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants // Cochrane Database Syst Rev. 2020. 1(1):CD004213. 53. Ohlsson A., Shah P.S. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants // Cochrane Database Syst Rev. 2020. 1(1):CD010061. 54. Ohlsson A., Walia R., Shah S.S. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants // Cochrane Database Syst Rev. 2020. 2(2):CD003481. 55. Patra A., Thakkar P.S., Makhoul M., Bada H.S. Objective Assessment of Physiologic Alterations Associated With Hemodynamically Significant Patent Ductus Arteriosus in Extremely Premature Neonates // Front Pediatr. 2021. 9:648584. 56. Perrone S., Manti S., Buttarelli L., Petrolini C., Boscarino G., Filonzi L., Gitto E., Esposito S.M., Nonnis Marzano F. Vascular Endothelial Growth Factor as Molecular Target for Bronchopulmonary Dysplasia Prevention in Very Low Birth Weight Infants // Int J Mol Sci. 2023.24(3):2729. 57. Philip R., Lamba V., Talati A., Sathanandam S. Pulmonary Hypertension with Prolonged Patency of the Ductus Arteriosus in Preterm Infants// Children (Basel). 2020. 7(9):139. 58. Philip R., Towbin J.A., Sathanandam S., Goldberg J., Yohannan T., Swaminathan N., Johnson J.N. Effect of patent ductus arteriosus on the heart in preterm infants // Congenit Heart Dis. 2019.14(1):33-36. 59. Potsiurko S., Dobryanskyy D., Sekretar L. Patent ductus arteriosus, systemic NT-proBNP concentrations and development of bronchopulmonary dysplasia in very preterm infants: retrospective data analysis from a randomized controlled trial // BMC Pediatr. 2021. 21(1):286. 60. Pranata R., Yonas E., Vania R., Prakoso R. The efficacy and safety of oral paracetamol versus oral ibuprofen for patent ductus arteriosus closure in preterm neonates - A systematic review and meta-analysis // Indian Heart J. 2020. 72(3):151-159. 61. Raju T.N. From Galen to Gross and beyond: a brief history of the enigmatic patent ductus arteriosus // J Perinatol. 2019. 39(11):1442-1448. 62. Rocha G. Consequences of early-onset preeclampsia on neonatal morbidity and mortality // Minerva Pediatr (Torino). 2023. 75(1):87-97. 63. Saito J., Ishikawa Y., Yokoyama U. Role of Tissue-Type Plasminogen Activator in Remodeling of the Ductus Arteriosus // Circ Rep. 2020. 2(4):211-217. 64. Sallmon H., Timme N., Atasay B., Erdeve Ö., Hansmann G., Singh Y., Weber S.C., Shelton E.L. Current Controversy on Platelets and Patent Ductus Arteriosus Closure in Preterm Infants // Front Pediatr. 2021.9:612242. 65. Sankar M.N., Benitz W.E. Does crossover treatment of control subjects invalidate results of randomized trials of patent ductus arteriosus treatment? // J Perinatol. 2020. 40(12):1863-1870. 66. Sankar M.N., Bhombal S., Benitz W.E. PDA: To treat or not to treat // Congenit Heart Dis. 2019. (1):46-51. 67. Schindler T., Smyth J., Bolisetty S., Michalowski J., Mallitt K.A., Singla A., Lui K. Early PARacetamol (EPAR) Trial: A Randomized Controlled Trial of Early Paracetamol to Promote Closure of the Ductus Arteriosus in Preterm Infants // Neonatology. 2021.118(3):274-281. 68. Shah S.D., Makker K., Zhang M., Harnett S., Aziz K.B., Hudak M.L. Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis // J Perinatol. 2022. 42(12):1654-1661. 69. Shepherd JL, Noori S. What is a hemodynamically significant PDA in preterm infants? // Congenit Heart Dis. 2019.14(1):21-26. 70. Smith A., El-Khuffash A.F. Defining "Haemodynamic Significance" of the Patent Ductus Arteriosus: Do We Have All the Answers? // Neonatology. 2020.117(2):225-232. 71. Su B.H., Lin H.Y., Chiu H.Y., Tsai M.L., Chen Y.T., Lu I.C. Therapeutic strategy of patent ductus arteriosus in extremely preterm infants // Pediatr Neonatol. 2020. (2):133-141. 72. Sung S.I., Chang Y.S., Ahn S.Y., Jo H.S., Yang M., Park W.S. Conservative Non-intervention Approach for Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants // Front Pediatr. 2020. 8:605134. 73. Surak A., Jain A., Hyderi A. Different approaches for patent ductus arteriosus in premature infants using acetaminophen // World J Pediatr. 2022. 18(4):243-250. 74. Vali P., Lakshminrusimha S., Pelech A., Underwood M., Ing F. Patent ductus arteriosus in preterm infants: is early transcatheter closure a paradigm shift? // J Perinatol. 2019. 39(11):1449-1461. 75. Vidavalur R. Efficacy and Costs of Three Pharmacotherapies for Patent Ductus Arteriosus Closure in Premature Infants // Paediatr Drugs. 2022. 24(2):93-102. 76. Villamor E., van Westering-Kroon E., Gonzalez-Luis G.E., Bartoš F., Abman S.H., Huizing M.J. Patent Ductus Arteriosus and Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Bayesian Meta-Analysis // JAMA Netw Open. 2023. 6(11): e2345299. 77. Wheeler C.R., Vogel E.R., Cusano M.A., Friedman K.G., Callahan R., Porras D., Ibla J.C., Levy P.T. Definitive Closure of the Patent Ductus Arteriosus in Preterm Infants and Subsequent Short-Term Respiratory Outcomes // Respir Care. 2022. 67(5):594-606. 78. Wu J., Wen Z.H., Liu D.D., Wu C.F., Zhang Y., Zhang L., Xu Y.L., Yang G., Jing C.X. Safety evaluation on different ventilation strategies set for neonatal respiratory distress syndrome: a network Meta-analysis // Zhonghua Liu Xing Bing Xue Za Zhi. 2020. 41(2):249-260. 79. Yan H., Ma F., Li Y., Zhou K., Hua Y., Wan C. The optimal timing of surgical ligation of patent ductus arteriosus in preterm or very-low-birth-weight infants: A systematic review and meta-analysis // Medicine (Baltimore). 2020. 99(9):e19356. 80. Yeung T., Shahroor M., Jain A., Weisz D., Jasani B. Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis // J Neonatal Perinatal Med. 2022.15(3):501-510. 81. Yurttutan S., Bozkaya A., Hüdayioglu F., Oncel M.Y. The effect of combined therapy for treatment of monotherapy-resistant PDA in preterm infants // J Matern Fetal Neonatal Med. 2019. 32(21):3662-3665. 82. Zhang Z., Lou X., Hua L., Jia X., Xu L., Zhao M. Cardiopulmonary Ultrasound-Guided Treatment of Premature Infants with Respiratory Failure and Patent Ductus Arteriosus: A Randomized, Controlled Trial // Indian J Pediatr. 2023. 90(11):1103-1109. References: [1] Ishtvan Seri, Charl'z Klaiman Gemodinamika i kardiologiya. Problemy i protivorechiya v neonatologii [Hemodynamics and cardiology. Problems and contradictions in neonatology]. Moskva. Logosfera. 2015. pp. 119-120. [in Russian]

Number of Views: 343

Key words: hemodynamically significant patent ductus arteriosus, echocardiography, premature newborns.

Category of articles: Reviews

Bibliography link

Omargazina B.S., Chuvakova T.K., Karin B.T., Jaxalykova K.K., Khamidullina Z.G. Hemodynamically significant patent duct arterius in premature newborn children. Literature review // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (2), pp. 171-183. doi 10.34689/SH.2024.26.2.020